Daré Bioscience, Inc.: notice of Nasdaq minimum bid deficiency

What happened

• Daré Bioscience, Inc. filed an 8-K reporting that on Sep 28, 2026 it received a letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying Daré that for the last 30 consecutive business days the closing bid price for Daré’s common stock was below the $1.00 per share Minimum Bid Price Requirement.
• The letter has no immediate effect on the listing and, in accordance with Nasdaq listing rules, Daré was provided an initial period of 180 calendar days, or until Mar 29, 2027, to regain compliance.

Key details

• Nasdaq notified Daré that the closing bid price was below $1.00 for 30 consecutive business days.
• Initial compliance period: 180 calendar days, ending Mar 29, 2027; compliance can be achieved if the closing bid is at least $1.00 for a minimum of 10 consecutive business days.
• If Daré does not regain compliance by Mar 29, 2027 it may be eligible for an additional 180 calendar day compliance period if it meets other listing standards and provides written notice of intent to cure, which could include a reverse stock split.
• The 8-K is signed by Sabrina Martucci Johnson, President and Chief Executive Officer, dated Oct 2, 2026.

Why it may matter

• Item reported: Item 3.01, "Notice of delisting or failure to satisfy a continued listing rule or standard," which covers Nasdaq notification that a company’s stock does not meet the Minimum Bid Price Requirement and the procedures and timeframes Nasdaq provides for regaining compliance.
• The filing states that Daré will monitor the closing bid price and consider options to regain compliance, and that there is no assurance it will regain or maintain compliance.

This filing does not show why the insider traded or why the company acted.